메뉴 건너뛰기




Volumn 526, Issue 2, 2012, Pages 146-153

Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays

Author keywords

ADCC; Antibody; Cell death; Complement; Phagocytosis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALEMTUZUMAB; BRENTUXIMAB VEDOTIN; CALCEIN; CALICHEAMICIN; CD16 ANTIGEN; CD20 ANTIBODY; CETUXIMAB; CHROMIUM 51; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; DACLIZUMAB; DUOCARMYCIN DERIVATIVE; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MAYTANSINE; MONOCLONAL ANTIBODY; PROPIDIUM IODIDE; RITUXIMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TRYPAN BLUE; VEDOTIN;

EID: 84865699475     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2012.02.011     Document Type: Review
Times cited : (95)

References (114)
  • 6
    • 77953653252 scopus 로고    scopus 로고
    • A.L. Nelson MAbs 2 2010 77 83
    • (2010) MAbs , vol.2 , pp. 77-83
    • Nelson, A.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.